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LETTERS TO THE EDITOR
The IASLC Lung
Cancer Staging Project:
Revision Proposal of
Pleural Effusion and
Controlateral Nodule
Staging
To the Editor:
The International oncology commu-
nity is urged to fully appreciate the major
effort of the International Association for
the Study of Lung Cancer (IASLC) in the
aim of revising lung cancer tumor, node,
metastasis (TNM) staging criteria. It is the
first time that a validation process of TNM
categories has been performed on an ex-
tremely wide database and case accrural
from all over the world.1
Here, we would like to provide
some suggestions in the proposal set-
ting, due to the major challenge of de-
fining the pleural effusion (PE)-related
disease, which, under the anatomic pro-
file is a locoregional disease. The inclu-
sion of PE by the IASLC committee in
the M1 category has been based on the
adverse prognostic weight more than an-
atomic spread. In our opinion, T4 cate-
gory might include PE distinguishing it
topographically from metastatic disease.
We would therefore suggest to define
the pleural involvement as a new T4b
category which, based on poor survival,
should be included in the stage IV to-
gether with M1. This classification
would allow to distinguish T4b from
T4a which is included in the IIIB group.
In this way, the stage IV, grouping PE
(T4b), controlateral nodule (M1a) and
other metastatic lesions at different sites
(M1b), would, in any case, include all
clinical conditions requiring a similar
therapeutic approach where the main-
stay would be systemic chemotherapy.
Our proposal take in account the emerg-
ing opportunities in staging nodules dis-
tinct from the primary tumor, including
T3 for the nodule in the same lobe of the
primary (T4 according to TNM 6) and
T4 for a nodule in a different ipsilateral
lobe (M1 according to TNM 6).2 In the
IASLC-International Staging Commit-
tee proposal, the new M1a category
would include two different conditions,
even with a similar prognostic impact:
PE or controlateral nodule.
In the “prospective data capture”
starting in 2008,1 by a large amount of
data collection, it might be useful to
differentiate clinicopathological settings
to define the role of controlateral lesions
in the most appropriate way. Within sur-
vival curves reported by Postmus et al.,3
PE and controlateral nodules appeared
close but distinguishable. It would be
interesting to maintain the chance of
recognizing a controlateral nodule as a
new primary even when histology does
not allow a clear definition, taking in
account that a new primary might allow
a curative resection with a clearly better
clinical outcome when compared with a
resectable metastatic nodule.
It is reasonable to predict that
emerging molecular profiling technolo-
gies4 will allow in the next future a clear
identification of a metastatic nodule
from a second primary, providing the
opportunity to further define the “best
stage,” which even at present provides a
more favorable estimate when compared
with “clinical stage” for PE.3 On these
bases, it is possible to predict that the
identification of true metastatic nodules
will further allow a better prognostic
discrimination of M1 (true metastatic
disease) when compared with the pro-
posed T4b PE (locoregional disease).
This concept can be understood in the
light of “Will-Rogers phenomenon” or
stage migration, which happens when
novel diagnostic or staging approaches
and technologies are translated in the
clinical practice. These changes will al-
low a better definition of close but rec-
ognizable prognostic conditions.5
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Reply to the Letter to
the Editor Entitled The
IASLC Lung Cancer
Staging Project: Revision
Proposal of Pleural
Effusion and
Contralateral Nodule
Staging, by V. Barbieri,
P. Tassone, and P.
Tagliaferri
In Reply:
We read with interest the letter
by Dr. Barbieri et al. regarding the
recommendations for changes in the
forthcoming edition of the tumor, node,
metastasis (TNM) classification for lung
cancer proposed by the International Stag-
ing Committee (ISC) of the International
Association for the Study of Lung Can-
cer.1 They raise two important issues: the
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